Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer
Status:
Recruiting
Trial end date:
2033-04-01
Target enrollment:
Participant gender:
Summary
This phase III trial compares the effects of shorter chemotherapy (chemo)-immunotherapy
without anthracyclines to usual chemo-immunotherapy for the treatment of early-stage triple
negative breast cancer. Paclitaxel is in a class of medications called anti-microtubule
agents. It stops cancer cells from growing and dividing and may kill them. Carboplatin is in
a class of medications known as platinum-containing compounds. It works in a way similar to
the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works
by killing, stopping or slowing the growth of cancer cells. Cyclophosphamide is in a class of
medications called alkylating agents. It works by damaging the cell's deoxyribonucleic acid
(DNA) and may kill cancer cells. It may also lower the body's immune response. Docetaxel is
in a class of medications called taxanes. It stops cancer cells from growing and dividing and
may kill them. Doxorubicin is an anthracycline chemotherapy drug that damages DNA and may
kill cancer cells. Pembrolizumab may stop the growth of tumor cells by blocking some of the
enzymes needed for cell growth. Shorter treatment without anthracycline chemotherapy may work
the same as the usual anthracycline chemotherapy treatment for early-stage triple negative
breast cancer.